Document Detail

Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency.
MedLine Citation:
PMID:  8250008     Owner:  NLM     Status:  MEDLINE    
To examine whether or not acquired alpha 2-plasmin inhibitor deficiency is associated with systemic fibrinogenolysis, we analyzed the fibrin and fibrinogen degradation products in eight patients with this condition in various disease states. The underlying disease was gastric cancer in three patients, metastatic prostatic cancer in two, acute promyelocytic leukemia in two, and abdominal aortic aneurysm in one patient. In all eight patients, the alpha 2-plasmin inhibitor level was reduced to less than 50% of normal, and plasmin-alpha 2-plasmin inhibitor complex levels were increased. Immunoblotting of serum using an antifibrinogen antibody detected a 250 kDa protein (corresponding to fragments X or DY) in all eight patients. Fragment Y and D monomer were detected in seven of the eight patients, indicating the occurrence of systemic fibrinogenolysis. However, they were not detected in one patient with metastatic prostatic cancer. To determine whether or not fibrinogen degradation was also occurring in the patient without fragment Y, we characterized the 250 kDa protein in all eight patients. The protein was found to be fragment X in the metastatic prostatic cancer patient without fragment Y, while it was fragment DY in the other seven patients. Thus, systemic fibrinogenolysis was present in all eight patients. In the two patients with metastatic prostatic cancer, the level of alpha 2-plasmin inhibitor gradually increased with the reduction of tumor size by treatment. Fragment X, fragment Y, and D monomer were not detected when the alpha 2-plasmin inhibitor level exceeded 60% of normal in both patients. In the other six patients fragment Y and D monomer also disappeared when the alpha 2-plasmin inhibitor level exceeded 60% of normal. These findings suggest that systemic fibrinogenolysis only occurs when the plasma levels of alpha 2-plasmin inhibitor falls below 60% of normal due to activation of the fibrinolytic system by various pathological conditions.
K Okajima; I Kohno; G Soe; H Okabe; K Takatsuki; B R Binder
Related Documents :
16276468 - Management of von willebrand disease in developing countries.
787458 - Studies on the prolonged bleeding time in von willebrand's disease.
21789968 - Analysis of hypersensitivity to oleaceae pollen in an olive-free and ash-free area by c...
10911718 - Identification of plasma antibody epitopes and gene abnormalities in japanese hemophili...
25356158 - Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spond...
24568478 - Clinical value of dual-phase 18f-fdg spect with serum procalcitonin for identification ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  45     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  1994 Jan 
Date Detail:
Created Date:  1994-01-06     Completed Date:  1994-01-06     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  16-24     Citation Subset:  IM    
Department of Laboratory Medicine, Kumamoto University Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aortic Aneurysm, Abdominal / complications,  therapy
Chromatography, Affinity
Fibrin Fibrinogen Degradation Products / metabolism
Fibrinogen / metabolism*
Leukemia, Promyelocytic, Acute / complications,  therapy
Middle Aged
Prostatic Neoplasms / complications,  therapy
Stomach Neoplasms / complications,  therapy
alpha-2-Antiplasmin / deficiency*
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/alpha-2-Antiplasmin; 9001-32-5/Fibrinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative defect of glycoprotein Ib in severe cirrhotic patients.
Next Document:  Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from pati...